|
5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide Suppliers list
|
| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
marketing1@energy-chemical.com |
|
| | 5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide Basic information |
| Product Name: | 5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide | | Synonyms: | 5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide;[2H11]-Glipizide;Glipizide d11Q: What is
Glipizide d11 Q: What is the CAS Number of
Glipizide d11 Q: What is the storage condition of
Glipizide d11 Q: What are the applications of
Glipizide d11;D11-Glipizide | | CAS: | 1189426-07-0 | | MF: | C21H16D11N5O4S | | MW: | 456.602959558 | | EINECS: | | | Product Categories: | | | Mol File: | 1189426-07-0.mol | ![5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide Structure](CAS/20200331/GIF/1189426-07-0.gif) |
| | 5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: slightly soluble,Ethyl Acetate: slightly soluble | | form | A solid |
| | 5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide Usage And Synthesis |
| Description | Glipizide-d11 is intended for use as an internal standard for the quantification of glipizide by GC- or LC-MS. Glipizide is a hypoglycemic agent. It inhibits ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells (IC50 = 6.4 nM). Glipizide induces insulin release from isolated rat pancreatic tissue with an EC50 value of 40 nM. Dietary administration of glipizide (5 mg/kg per day for 10 days) increases the number of insulin receptors on isolated and purified mouse liver plasma membranes. It reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and streptozotocin (STZ; ) when administered orally at a dose of 5 mg/kg. Formulations containing glipizide have been used in the treatment of type 2 diabetes. | | Uses | Labelled Glipizide (G410225). A sulfonylurea hypoglycemic agent. Used as an antidiabetic. | | References | [1] B J ZüNKLER. Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells.[J]. Naunyn-Schmiedeberg’s archives of pharmacology, 1988, 337 2: 225-230. DOI: 10.1007/bf00169252
[2] A HERCHUELZ W J M. Insulinotropic potency of glipizide in vitro.[J]. Diabetologia, 1973: 309-310. DOI: 10.1007/bf01218439
[3] MARK N. FEINGLOS HAROLD E L. Sulphonylureas increase the number of insulin receptors[J]. Nature, 1978, 276 5684: 184-185. DOI: 10.1038/276184a0
[4] K. SRINIVASAN. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening[J]. Pharmacological research, 2005, 52 4: Pages 313-320. DOI: 10.1016/j.phrs.2005.05.004 |
| | 5-methyl-N-[2-[4-[(1,2,2,3,3,4,4,5,5,6,6-undecadeuteriocyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]pyrazine-2-carboxamide Preparation Products And Raw materials |
|